Genprex (GNPX) Channelchek C-Suite Series, CEO Rodney Varner interview with Noble's Dr. Ahu Demir Transcript
Welcome to the C-Suite series on Channelchek. I'm Michael Kupinski, the Director of Research at Noble Capital Markets. Noble is the source of all equity research on Channelchek and the source for small and microcap companies.
In this program, we are featuring Genprex. The stock symbol is GNPX. Noble analyst Ahu Demir will interview CEO Rodney Varner. Genprex is a unique company. It has a gene therapy that targets lung cancer and has a program that targets diabetes. The stock has been on a tear, up over 1,000% in the past year.
In this interview management highlights why the stock is still undervalued. If you'd like to get more research on Genprex, I encourage you to take a look at channelchek.com. Type in the stock symbol GNPX in the search box in the top left section of the site. Before I turn it over to Ahu, I encourage you to stick around for closing comments, when Ahu and I discuss the key takeaways from this interview. Ahu, take it away.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |